Publications
- Komentář k analýze2023 | First Faculty of Medicine
- Ground-breaking ADAURA trial - osimertinib as adjuvant therapy of EGFR-mutated NSCLC2022 | First Faculty of Medicine
- Clinical experience with durvalumab treatment2021 | First Faculty of Medicine
- NSCLC (Non-Small Cell Lung Cancer) and kidney tumor in the elderly patient with response to chemoimmunotherapy2021 | First Faculty of Medicine
- KRAS mutations in non-small cell lung cancer and options of treatment2020 | First Faculty of Medicine
- The role of durvalumab in the treatment of stage III NSCLC2020 | First Faculty of Medicine
- First-line pembrolizumab for metastatic non-small-cell lung cancer2020 | First Faculty of Medicine
- Complete response to pembrolizumab in a patient with stage IV NSCLC (non-small cell lung cancer)2020 | First Faculty of Medicine
- New biomarkers, molecules and therapeutic sequences for non-small lung carcinoma in the era of precision medicine : (9.-10. 5. 2019, Institut du Cervau et de la Moelle Épiniere, Paris, France)2019 | First Faculty of Medicine
- Pembrolizumab v léčbě nemalobuněčného plicního karcinomu2019 | First Faculty of Medicine
Loading network view...